LY3882535
Phase 1
Eli LillyLY3882535 is one of 51 therapeutic programs targeting Alzheimer disease. It is currently in Phase 1.
1
Indications
0
Total Trials
0
Active Trials
50
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
171 competitors in Alzheimer Disease
#DrugCompanyPhaseTrials
1Kisunla
Eli LillyPhase 3
Tirazone
SanofiPhase 3
Karxt
Bristol-Myers SquibbPhase 3
Karx-EC
Bristol-Myers SquibbPhase 3
Aquasol E
NNational Eye Institute (NEI)
Phase 3
Aricept
EisaiPhase 2
Naproxen Sodium
BayerPhase 3
Exelon
NovartisPhase 2
Namenda
AbbViePhase 2
Leukine
SanofiPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for LY3882535. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1
- Company